microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations by Duregon, E et al.
 
 
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 [Human pathology, 45 (8), 2014, DOI 10.1016/j.humpath.2014.04.005] 
 ovvero [Duregon E, Rapa I, Votta A, Giorcelli J, Daffara F, Terzolo M, Scagliotti GV, 
Volante M, Papotti M., 45, Elsevier, 2014, pagg.1555-1562] 
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
[http://www.sciencedirect.com/science/article/pii/S0046817714001580] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
micro-RNA EXPRESSION PATTERNS IN ADRENOCORTICAL CARCINOMA VARIANTS AND CLINICAL 
PATHOLOGICAL CORRELATIONS  
 
Eleonora Duregon, MD, Ida Rapa, BSc, Arianna Votta, Jessica Giorcelli, Fulvia Daffara*, MD, Massimo 
Terzolo*, MD, Giorgio V. Scagliotti, MD, Marco Volante, MD, Mauro Papotti, MD 
 
Departments of Oncology, and of *Clinical & Biological Sciences, University of Turin at San Luigi 
Hospital, Orbassano, 10043, Torino, Italy  
 
KEY WORDS:  adrenal cortex, carcinoma, micro-RNA, variant, prognosis 
Running title: miRNA expression in adrenocortical carcinoma 
Conflict of interest statement: All Authors declare the absence of any potential conflict of interest. 
Source of support: Work supported by grant from the Italian Association for Cancer Research (AIRC, 
Milan, grant no. IG/10795/2010 to MP) and University of Turin (ex-60% grants to MV and MP). ED 
and IR are students of the Ph.D program in the Doctorate School of “Biomedical Sciences and 
Oncology” at the University of Turin. 
 
Address for correspondence:  Marco Volante, MD 
Department of Oncology, University of Turin at San Luigi Hospital,  
Regione Gonzole 10, 10043 Orbassano, Torino, Italy 
Phone +390116705464; Fax: +390119026753; email: marco.volante@unito.it  
 
 
 
ABSTRACT  
 
Several miRNAs were shown to be de-regulated in adrenocortical carcinoma as compared to 
adenoma, but a detailed assessment of their expression in its histological variants and correlation 
with clinical-pathological characteristics has not been performed, so far. Our aim was to assess the 
expression of five selected miRNAs (IGF2 gene-related miR-483-3p and 5p, hypoxia-induced miR-210, 
miR-195 and miR-1974) in a series of 51 adrenocortical carcinomas (35 classical, 6 myxoid, and 10 
oncocytic) as compared to clinical and pathological features and immunohistochemical expression of 
prognostic markers, including steroidogenic factor 1 (SF-1), p53, β-catenin and glucose transporter 1 
(GLUT-1). Oncocytic carcinomas had a reduced expression of miR-483-3p (p= 0.0325), miR-483-5p (p= 
0.0175) and miR-210 (p= 0.0366), as compared to other histotypes. Over-expression of miR-210 was 
associated to the presence of necrosis (p= 0.0035), high Ki-67 index (p=0.0013) and high GLUT-1 
expression (p=0.0043), whereas an inverse correlation with mitotic rate was observed in cases with 
high miR-493-3p (p= 0.0191) and miR-1974 (p= 0.0017) expression. High miR-1974 was also 
associated with low Ki-67 (p= 0.0312) and ENSAT stage (p=0.0082), and negative p53 (p=0.0013). At 
univariate analysis myxoid/classical histotype (p=0.026), high miR-210 (p=0.0465), high SF-1 protein 
(p=0.0017), high Ki-67 (p=0.0066) and high mitotic index (p=0.0006) were significantly associated to a 
shorter overall survival, the latter being the sole independent prognostic factor at multivariate 
analysis (p= 0.017).  In conclusion, a) miR-483-3p, miR-483-5p and miR-210 are differentially 
expressed in adrenocortical carcinoma variants; b) high miR-210 is associated with clinico-
pathological parameters of aggressiveness and a poor prognosis. 
INTRODUCTION  
 
Adrenocortical carcinoma is a rare malignancy with a highly aggressive biological behavior (20-40% 
five-year survival) [1,2]. The diagnosis of adrenocortical carcinoma is currently based on the Weiss 
System [3,4], a scoring procedure that can easily classify most cases, but is particularly challenged in 
tumors with incomplete morphological signs of malignancy, even if used by experts and specifically 
trained pathologists [5], and in adrenocortical carcinoma morphological variants, i.e. the myxoid and 
the oncocytic [2]. An inter-observer validation study recently showed that the Reticulin Algorithm, 
previously proposed as a diagnostic approach alternative to the Weiss System, is highly accurate and 
reproducible to define malignancy also in adrenocortical carcinoma special histotypes [6]. However, 
while the morphological distinctiveness of myxoid and oncocytic variant has already been thoroughly 
characterized and reviewed [7-10], their immunohistochemical and molecular phenotype has been 
addressed so far by very few studies only [8,10-13].  
MicroRNAs (miRNAs) are short noncoding RNAs, 18 to 25 nucleotides in length, which regulate gene 
expression either by post-transcriptional regulation of gene expression leading to target mRNA 
degradation or by the repression of its translation with consequent decrease in the particular protein 
levels or even by up-regulation of their targets [14].  
To date, several studies analyzed the miRNA  expression profile in adrenocortical neoplasms, mainly 
aimed at finding out those useful to differentiate adenomas from carcinomas. However, the 
expression of none of these miRNAs has been tested within the group of adrenocortical carcinomas 
in terms of variability among variants or detailed association with clinical or pathological features. 
Therefore, we designed a study to explore the expression of five miRNA in a series of 51 
adrenocortical carcinomas (including 35 classical, six myxoid, and 10 oncocytic) in comparison with 
clinical and pathologic features and immunohistochemical expression of markers related to biological 
or clinical aggressiveness, including steroidogenic factor 1 (SF-1), p53, β-catenin and glucose 
transporter 1 (GLUT-1). Three miRNA were selected since those most consistently reported to be de-
regulated in both tissue and serum of adrenocortical carcinoma patients: miR-483-3p and 5p, which 
are transcribed from an intronic sequence of IGF2 gene and are commonly over-expressed in 
adrenocortical carcinoma, and miR-195 which is conversely down-modulated in adrenocortical 
carcinoma [15-20]; moreover, due to the peculiar metabolic and ultrastructural features of oncocytic 
cells which are the hall-mark of the oncocytic variant, two additional miRNAs - significantly de-
regulated in adrenocortical cancer - were selected based on their involvement in the hypoxic 
pathway (miR-210) [21] or a peculiar mitochondrial localization (miR-1974) [22]. 
We here show that: a) miR-483-3p, miR-483-5p and miR-210 are differentially expressed among 
histological variants of adrenocortical carcinoma; b) high miR-210 levels are associated with clinical 
and pathological parameters of aggressiveness (necrosis and Ki-67 proliferation index) and a shorter 
overall survival.  
 
MATERIAL AND METHODS 
 
Tissue collection - 51 adrenocortical tumors having a Weiss score ≥3 [3,4] (including six myxoid and 
10 oncocytic) were retrieved from the pathology files of the University of Turin. The 10 oncocytic 
tumors were also reclassified according to the Lin-Weiss-Bisceglia scheme [9], and all proved 
malignant even with this more accurate score.  A control series of 47 unpublished conventional 
adrenocortical adenomas (all with a Weiss score <1) was also tested. All these cases had paraffin 
embedded tissue blocks suitable for miRNA extraction. The majority of adrenocortical carcinoma 
patients were treated at our Institution, which serves as a referral center for this disease in Italy. The 
histo-pathological features of all cases belonging to this data set have already been characterized as 
detailed in previous publications by our group [6, 8, 10, 13, 23, 24]. For all of them, clinical data about 
treatment and outcome were updated (Table 1). The study received ethical approval from the local 
Review Board of our Institution. 
 
miRNA expression analysis by means of real-time PCR - miRNA were extracted from paraffin 
embedded  tissues using miRNeasy Kit (Qiagen srl Italy, Milan, Italy) according to manufacturer’s 
instructions. Complementary DNA was synthesized with specific stemloop primers using 100ng total 
RNA in 15 μl total reaction. The reaction consisted of the following components: 100mM dNTP’s, 10x 
RT Buffer, RNase Inhibitor, 5x TaqMan microRNA RT primer and Multiscribe RT enzyme and was 
carried out in a thermal cycler machine (Eppendorf, Hamburg, Germany) at the following conditions: 
16°C for 30 minutes, 42°C for 30 minutes, 85°C for 5 minutes, 4°C for 10 minutes. 
The following Taqman microRNA assays were employed by means of real-time PCR: hsa-miR-483-5p 
(code 002338), hsa-miR-483-3p (code 002339), hsa-miR-210 (code 000512), hsa-miR-195 (code 
000494) and hsa-miR-1974 (code 121209_mat) (Life technologies, Carlsbad, CA, USA). Results were 
normalized using the 2-ΔΔCT-method (Pfaffl MW, 2001) using expression of U6-snRNA and the value 
for each miRNA in the case with the lowest expression as the reference. Reactions were carried out 
according to the following parameters in an ABI Prism 7900HT Sequence Detection System (Life 
technologies): 95°C for 10 minutes, 95°C for 15 seconds, 60°C for 60 seconds for 40 cycles.  
 
Immunohistochemistry – 46 out of 51 adrenocortical carcinomas herein analyzed for miRNA 
expression were included in TMAs assembled as previously described [13] using three cores with a 
diameter of 2 mm from each case. Five μm thick paraffin sections serial to those used for 
conventional hematoxylin and eosin staining were obtained for immunohistochemical reactions. Raw 
data of SF-1 scores already obtained in 45 out of 46 cases were retrieved for comparison [13]; 46 out 
of 51 cases had Ki-67 information already available from a recent study from our group [24]. 
Additional stainings included: p53 (DakoCytomation, Glostrup, Denmark; clone D07, diluted 1/300), 
β-catenin (Santacruz, polyclonal, clone H102, diluted 1/200), and GLUT-1 (Thermo scientific, clone 
SPM498, diluted 1/200). A biotin-free, dextran chain-based detection system (EnVision, Dako) was 
used according to a standard protocol, and diaminobenzidine served as the chromogen. 
 
Staining interpretation and scoring system – All slides were analyzed by two pathologists (ED, MV), 
and all samples were considered adequate for all antibodies in the presence of two or more suitable 
cores after sectioning and staining procedures. Staining was assessed for each antibody as follows:  
SF-1, semiquantitative scoring system based on the evaluation of nuclear staining:  score 0= no 
staining; score 1= focal (< 50% of the core) staining; score 2= diffuse (≥ 50% of the core) staining; p53, 
manual count of positive nuclei on 1000 cells and relative percentage; β-catenin, positive in presence 
cytoplasmic and/or nuclear staining; GLUT-1, positive only in presence of cell membrane staining.  
 
Statistical analysis – Reciprocal correlations among the different miRNA expression levels and 
between miRNAs and mitotic/proliferation indexes were made using a two-tailed Spearman’s test. 
Expression levels of miRNAs were compared to clinical and pathological characteristics and staining 
patterns for each antibody tested using Chi-square or Student’s t tests, as appropriate. The 
prognostic impact of clinical and pathological parameters available (sex, age, hormonal secretion, 
weight, size, Weiss score, Ki-67 proliferation index, mitotic count, ENSAT stage and the reactivity to 
SF-1, p53, β-catenin and GLUT-1 antibodies) was tested in univariate overall survival analysis using 
the Kaplan–Meier product limit estimate of survival distribution and the Log Rank test. All parameters 
with a significant impact on survival at univariate analysis were included in multivariate analysis using 
the Cox proportional hazard model. Statistical significance was set at p<0.05. All tests were 
performed using GraphPad Prism version 6.0 and IBM SPSS Statistics Version 20. 
 
RESULTS 
  
Differential expression of miRNAs investigated in adenoma vs carcinoma samples. 
All but one miRNA were significantly de-regulated in carcinoma vs adenoma samples. In particular, in 
agreement with what previously reported in the literature, miR-483-3p, miR-483-5p and miR-210 
were significantly up-regulated whereas miR-195 was down regulated in carcinomas (p value: 
<0.0001 for all four miRNAs) (Figure 1). By contrast, miR-1974 was not differentially expressed in 
benign vs malignant adrenocortical samples of our series (p=0.99). 
 
Reciprocal correlation among expression levels of miRNAs investigated in adrenocortical carcinoma 
samples - miR-483-3p and miR-483-5p (r= 0.7380, p=<0.0001) and miR-210 and miR-1974 (r= 0.4071, 
p=0.003) were highly reciprocally correlated. A slight inverse correlation among miR-1974 and miR-
483-3p (r= -0.2939, p= 0.0449) was also observed (Table 2).  
 
Correlation of miRNA expression levels and clinical pathological parameters including histological 
variants - Significantly reduced expressions of miR-483-3p, miR-483-5p and miR-210 were observed 
in oncocytic as compared to classical and myxoid histotypes (p= 0.0325, p= 0.0175, p= 0.0366 for 
miR-483-3p, miR-483-5p and miR-210, respectively) (Figure 2). As far as  concern clinical and 
pathological parameters, expression levels of any of the miRNAs analyzed were associated with 
patient age, tumor size, weight and total Weiss Score (Table 3). High miR-210 levels were associated 
to male sex (unpaired t-test, p= 0.0003), presence of necrosis (unpaired t-test, p= 0.0035) and high Ki-
67 proliferation index (unpaired t-test, p=0.0013). Although the association between high miR-210 
and high mitotic rate was not statistically significant (unpaired t-test, p=0.4963), it was slightly 
positively correlated using the Spearman’s linear correlation test  (r= 0.2898, p= 0.0457). On the 
contrary, miR-493-3p and miR-1974 levels were higher in cases with low mitotic/proliferation indices 
(miR-493-3p and mitotic rate, unpaired t-test, p= 0.0191; miR-1974 and mitotic count, unpaired t-
test, p= 0.0017; miR-1974 and Ki-67 proliferation index, unpaired t-test, p= 0.0312). High miR-1974 
levels were also associated with low ENSAT stage (p=0.0082). Finally, miR-195 levels were slightly 
higher in functioning tumors (unpaired t-test, p=0.0457).  
 
Correlation of miRNA expression levels with phenotypical markers of aggressiveness and disease 
outcome - Membrane GLUT-1 staining was significantly associated with high miR-210 levels 
(p=0.0043), while negative p53 and β-catenin were associated with high levels of miR-1974 (unpaired 
t-test, p=0.0013) and miR-195 (unpaired t-test, p= 0.011), respectively. No statistically significant 
correlation was found among the miRNA investigated and SF-1 protein expression. At univariate 
survival analysis, myxoid or classical histotype [Log rank test, p=0.026, HR=0.1445 (CI 0.12-0.87)], 
mitotic count ≥ 11 *Log rank test, p=0.0006, HR=0.2398 (CI 0.07-0.46)], Ki-67 proliferation index ≥ 20 
[median value; Log rank test, p=0.0066, HR=0.2827 (CI 0.09-0.59)], high SF-1 protein expression [Log 
rank test, p=0.0017, HR=0.2056 (CI 0.06-0.68)], and high miR-210 expression [Log rank test, p=0.0465, 
HR=0.4213 (CI 0.16-0.98)] were associated with a shorter overall survival  (Table 4 and Figure 3). A 
trend to significance was observed for functioning carcinomas (p=0.051), nuclear p53 (p= 0.063), 
membrane GLUT-1 (p= 0.065), nuclear β-catenin (p= 0.13) and low miR-1974 levels (p= 0.011). At 
multivariate survival analysis, mitotic count confirmed to be the sole independent prognostic factor  
(p= 0.017).  
 
DISCUSSION 
 
In a series of adrenocortical carcinomas we investigated the expression of five miRNA, known to be 
de-regulated in this tumor type, demonstrating a differential expression of miR-483-3p, miR-483-5p 
and miR-210 in histological variants and a correlation with clinical and pathological features 
associated with aggressive behavior, with special reference to miR-210.  
MiR-483-3p and miR-483-5p are derived from different arms of the same miRNA precursor, within 
the second intron of IGF2 gene at 11p15.5. In NCI-H295R adrenocortical carcinoma cell line, miR-483-
5p promotes cell proliferation, but has no effect on apoptosis [18], while miR-483-3p, targeting the 
pro-apoptotic protein PUMA [25], protects cells from apoptosis [18]. They were consistently found to 
be over-expressed in comparison with adenomas [15-20] and reciprocally correlated [15]. As 
expected, we found a strong reciprocal correlation among miR-483-3p and miR-483-5p (r= 0.7380, 
p=<0.0001). Moreover, we found a significantly lower expression in the oncocytic variant of 
adrenocortical carcinoma, whose meaning remains to be defined, but supports a different and 
specific phenotype also at the molecular level for this special type [10,26]. Interestingly, high miR-
493-3p levels were also a feature of low proliferating tumors. The above findings, apparently in 
contrast to the oncogenic functions of miR-483-3p mentioned above [18,25], are in agreement with 
recent data on the possible alternative function of this same miRNA as an onco-suppressor, acting as 
negative modulator of cell proliferation and pro-apoptotic molecule, at least in skin cells [27].  
MiR-210 maps to the same 11p15.5 chromosome locus as miR-483-3p and miR-483-5p, and was also 
reported to be up-regulated in adrenocortical carcinoma [18,21]. As for miR-483-3p and miR-483-5p, 
miR-210 was significantly down-regulated in the oncocytic variant as compared to the classical and 
myxoid types. This observation is of particular interest considering that oncocytic cells (at least in the 
thyroid and kidney) display a genetic disassembly of the respiratory complex I, which in turn 
contributes to the inability of stabilizing HIF1alpha [28]. Interestingly, miRNA-210 high expression was 
also positively associated with parameters of hypoxia, like necrosis and GLUT-1, and aggressive 
biological behavior such as mitotic rate and Ki-67 proliferation index, that are usually low in oncocytic 
tumors.  
MiR-195 is located at 17p13.1,  where also the TP53 gene maps. A loss of heterozygosity of this 
chromosome region has been reported in 84% of adrenocortical carcinomas and 30% of adenomas 
[29,30]. Accordingly, miR-195 is down-regulated in adrenocortical carcinomas both at the tissue 
[15,17,19] and serum levels [20]. In our series, low miR-195 was a feature of functioning and β-
catenin negative tumors, but no correlation was found with p53 protein expression. 
As to concern miR-1974, which was reported to be down-modulated in adrenocortical carcinoma by 
Ozata et al. [18], we initially hypothesized an aberrant expression in oncocytic tumors due to its 
peculiar localization in the mitochondria [22]. This miRNA has been currently re-challenged as a 
mitochondrial DNA-coded tRNA (mirbase miRNA accession: MI0009984; www.mirbase.org), but it 
appeared to be associated with adrenocortical tumors with low aggressiveness. In fact, no correlation 
with the histological variant was observed, but high miR-1974 levels were associated with low mitotic 
and Ki-67 proliferation indexes and low ENSAT stage. However, the significance of miR-1974 as a 
biomarker in adrenocortical tumors is of limited value since no difference in expression levels was 
detected between adenomas and carcinomas in our series. 
In our case series, at univariate analysis histological variant and miR-210 were found to have a strong 
impact on survival together with well established prognostic factors such as mitotic count, Ki-67 
proliferation index and high expression levels of SF-1 [13,24,31,32]. Concerning the importance of 
histological variant in ACC clinical outcome, we have confirmed the results of a retrospective survival 
analysis provided by Wong et al. [26], in which was shown a better prognosis for malignant 
adrenocortical neoplasm showing predominant oncocytic features in comparison with those of 
classical type. The prognostic value of miR-210 has already been demonstrated in breast [33], 
pancreatic [34], head and neck carcinomas [35], pediatric osteosarcoma [36], and glioblastoma [37]. 
However, after testing all the above parameters in multivariate analysis, mitotic count remained the 
single independent significant parameter in our series, although a trend to significance was 
maintained for non-oncoytic histotype and miR-210. No other miRNA significantly influenced overall 
survival in the case series analyzed.   
 
CONCLUSIONS 
 
Adrenocortical carcinoma variants have morphological, immunophenotypical and molecular 
peculiarities, including a differential miRNA expression profiles. In addition, high miR-210 expression 
should be included among molecular features of potential prognostic impact.  
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LEGENDS FOR FIGURES  
 
Figure 1. Box plots demonstrating the differential expression of four out of five miRNAs investigated in 
adrenocortical adenomas as compared to carcinomas. All p values <0.0001. 
 
Figure 2. Box plots demonstrating the differential expression of miRNAs investigated in adrenocortical 
carcinoma variants. Lower panels illustrate representative images of architectural patterns in classic, 
myxoid and oncocytic adrenocortical carcinoma cases (Hematoxylin and eosin staining, original 
magnification for all pictures 200x) 
 
Figure 3. Overall survival curves according to miR-210 expression levels, segregated according to the 
median value 
 
 
Table 1. Clinical pathological features of 51 adrenocortical carcinomas analyzed for microRNA 
expression. 
 
Parameter  
F/M ratio 1.38 
Age, mean (years) [range] 47 [20-79] 
Functional status  
(Not known:  7) 
Not functioning: 21 
Functioning: 23  
(cortisol: 15, cortisol+androgen:4, androgen: 2, 
aldosterone: 2) 
Mean size (cm) [range] 11. 5 [2-30] 
Mean weight (g) [range] 561 [8-3200] 
ACC variant Classical: 34 
Myxoid: 7 
Oncocytic (pure/mixed): 10 (7/3) 
Weiss Score distribution 3-4: 17 
5-6: 15 
7-8-9: 29 
ENSAT stage (Not known:  12) 1-2: 27 
3-4: 12 
Disease status (lost to FU: 2) NED/DOC: 19 
AWD: 10 
DOD: 20 
Median overall survival  (months) 60 [4-420] 
(classical + myxoid ACC: 59, oncocytic ACC: 79)  
Adiuvant mitotane 17 
 Abbreviations: ACC, adrenocortical carcinoma; M, male; F, female; FU, follow up; NED, not evidence of 
disease; DOC, died of other cause; AWD, alive with disease; DOD, died of disease. 
 
 
Table 2. Reciprocal correlations among miRNAs investigated.  
 
marker miRNA 483-3p miRNA 483-5p miRNA 
210 
miRNA 
195 
miRNA 483-5p r= 0.7380 
p= <0.0001 
-- --  
miRNA 210 r= 0.1855 
p= 0.1924 
r= 0.0467 
p=0.7444 
-- -- 
miRNA 195 r= -0.1937  
p=0.1733 
r= - 0.2489 
p= 0.0782 
r= 0.1072 
p=0.4538 
-- 
miRNA 1974 r= -0.2939 
p= 0.0449 
r= 0.1671 
p= 0.2413 
r= 0.4071 
p= 0.0030 
r= -0.0181 
p= 0.8997 
 
 
Table 3. Correlation between miRNA expression and clinical pathological parameters in adrenocortical carcinomas. 
 
      Parameter  
miR-483-3p miR-483-5p miR-210 miR-195 miR-1974 
mean p mean p mean p mean p mean p 
Age 
≤45 
>45 
410.9 
281.6 
0.0614 
330.5 
179.1 
0.0819 
20.03 
8.924 
0.4628 
9.020 
12.32 
0.2207 
11.25 
14.48 
0.4241 
Sex 
F 
M 
299.7 
366.2 
0.1532 
252.4 
293.9 
0.9701 
5.322 
65.33 
0.0003 
7.790 
12.22 
0.4594 
12.76 
12.06 
0.5838 
Size (cm) 
≤11 
>11 
302.3 
348.6 
0.6616 
291.9 
161.1 
0.6558 
10.32 
32.69 
0.3048 
8.165 
10.38 
0.7122 
15.49 
11.06 
0.6069 
Weight (g) 
≤260 
>260 
306.2 
512.2 
0.4432 
274.2 
446.2 
0.4935 
15.93 
27 
0.7819 
8.055 
11.40 
0.3107 
13.27 
9.27 
0.6283 
Functional 
status 
func. 
not func. 
181.5 
382.3 
0.1868 
185.1 
327.8 
0.1190 
21.59 
8.516 
0.4011 
7.95 
12.43 
0.0454 
7.52 
17.20 
0.1297 
ENSAT 
stage 
1-2 
3-4 
353.3 
153 
0.0521 
256.5 
295.8 
0.4244 
15.39 
22.85 
0.7945 
10.38 
12.32 
0.7044 
16.35 
5.13 
0.0082 
Weiss 
score 
3-4-5 
6-7-8-9 
382.4 
181.5 
0.5720 
217.4 
295.8 
0.4880 
7.557 
32.69 
0.0545 
10.38 
10.27 
0.4628 
15.49 
10.06 
0.0677 
Histologic 
type 
classical 
myxoid 
oncocytic 
432.9 
326.7 
54.5 
0.0325 
389.5 
319.3 
52.12 
0.0175 
206.9 
99.27 
27.19 
0.0366 
19.71 
70.86 
7.081 
0.1503 
23.28 
7.026 
88.53 
0.2853 
Necrosis 
present  
absent 
353.3 
292 
0.8470 
221.4 
288 
0.9480 
38.31 
4.92 
0.0035 
7.84 
10.83 
0.5184 
12.06 
12.76 
0.7874 
Mitotic count 
x50HPF* 
<11 
>11 
410.6 
176.7 
0.0191 
 
280.2 
252.4 
0.3305 
12.07 
34.23 
0.4963 
10.38 
9.93 
0.3412 
22.36 
6.230 
0.0017 
Ki-67 
index* 
<20 
>20 
382.4 
180.6 
0.1942 
302.3 
237.4 
0.3853 
5.217 
55.63 
0.0013 
8.325 
10.83 
0.8823 
27.81 
10.06 
0.0312 
SF-1 
low 
high 
336.2 
179.2 
0.4733 
173.7 
270.2 
0.7714 
10.08 
43.82 
0.0979 
10.48 
8.845 
0.6289 
12.06 
9.69 
0.1423 
p-53 
negative 
positive 
325.1 
15.09 
0.0548 
256.5 
11.20 
0.3439 
20.03 
5.217 
0.2266 
10.10 
12.32 
0.7595 
17.20 
5.13 
0.0013 
β-catenin 
negative 
positive 
336.2 
180.6 
0.2768 
256.5 
182.3 
0.6305 
15.46 
20.33 
0.5473 
18.28 
5.98 
0.0110 
12.06 
7.67 
0.4848 
GLUT-1 
negative 
positive 
337.8 
292.0 
0.8860 
217.4 
288.0 
0.7034 
10.08 
65.27 
0.0043 
10.38 
10.83 
0.7579 
9.270 
16.19 
0.4571 
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 1 
Table 4. Univariate overall survival analysis 2 
 3 
Parameter Hazard Ratio 
(logrank) 
95% CI p 
Female sex 1.182 0.4807-2.902 0.7185 
Age ≤45 0.9130 0.3749-2.212 0.8390 
Presence of hormone secretion 0.3844 0.1690-0.9919 0.0511 
ENSAT stage 3-4 0.5632 0.1954-1.398 0.1991 
Size >11 cm 0.6701 0.2635-1.704 0.7070 
Weight >260 g 1.187 0.4552-3.087 0.7253 
Weiss Score >6 0.8818 0.3654-2.116 0.7762 
Mitotic count x 50HPF >11* 0.2398 0.0682-0.4553 0.0006 
Ki-67 >20* 0.2827 0.0978-0.5869 0.0066 
Myxoid and classical histotype* 0.1445 0.1195-0.8670 0.0266 
High expression SF-1* 0.2056 0.0623-0.6773 0.0017 
Positive p53 0.2665 0.0675-1.075 0.0632 
Positive β-catenin 0.4105 0.1618-1.042 0.1318 
Positive GLUT-1 0.4152 0.1631-1.057 0.0652 
High miR-483-3p 1.091 0.4518-2.634 0.8466 
High miR-483-5p 1.4 0.5700-3.437 0.4631 
High miR-210*  0.4213 0.1603-0.9690 0.0465 
Low miR-195 1.33 0.5522-3.217 0.5228 
Low miR-1974 2.062 0.8477-4.905 0.1131 
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*: parameters included in multivariate analysis: mitotic index: p=0.017; Ki-67: p= 0.167; histotype: p= 4 
0.355; SF-1: p= 0.236; miR-210: p= 0.219. 5 
6 
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Figure 1. 7 
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Figure 2. 11 
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Figure 3. 15 
 16 
